AstraZeneca versus GSK Results and Dividend Summaries

November 6, 2012

Both GSK and AstraZeneca announced their quarterly results. Currently, UK’s pharma majors provide dividend yields of between 5 percent and 6 percent.

I have extensively reported on both GSK’s third quarter results, which you can access Here and AstraZeneca’s which you can access Here.


Though AstraZeneca is not a quarterly dividend payer, it still reported on its third quarter to 30 September. Worryingly, revenue declined further following the loss of exclusivity on several brands which took its toll on profits – resulting in a 14 percent fall in core earnings per share for the nine months.

On a more positive note, on his first day in the job, the new CEO announced that AstraZeneca’s share buybacks have now been suspended. Not a moment too soon I would say as net cash flow has turned into net debt of US$3.8bn compared with net cash of $2.8bn at the start of the year.

Click Here for our take on AstraZeneca’s results and its dividend prospects


Together with its third quarter results, GSK also announced a review of its European operations as sales fell 8 percent in the third quarter. Continued pressure on drug prices in Europe, together with lower demand for vaccines hit overall sales at the group.

The group is expecting fourth quarter sales to pick up, but full year sales are now expected to be flat year-on-year, and that is assuming there is no further deterioration in Europe.

The dividend was up a penny, at 18 pence – going ex-dividend on 14 November and payable on 3 January 2013 – an improvement on last year’s third quarter pay-out of 17 pence.

Click Here for more information on GSK’s results and dividend prospects.

Are GSK’s shares currently historically overvalued?

Buying dividend paying shares when they are priced too high will often lead to long-term disappointing returns.

Our unique share valuation service provides you with information the share prices at which many dividend paying companies are historically undervalued and overvalued. Our proprietary financial strength database provides you with information whether these companies can sustain and increase their dividend payments.

Find out if GSK shares are currently historically undervalued, overvalued or trading somewhere in-between’.

Maximise your long-term returns: Enter and exit the stock market at the right time while receiving increasing dividends from companies that have been paying dividends for decades and are financially strong.

Subscribe Now

AND remember our life time guarantee!

Once you are a subscriber you will never pay more for your subscription!

Click Here To Return to Dividend Income Blog

What next?

Accept Cookies?